Skip to main content
Top
Published in: BMC Infectious Diseases 1/2005

Open Access 01-12-2005 | Research article

Balance of IL-10 and Interferon-γ plasma levels in human visceral leishmaniasis: Implications in the pathogenesis

Authors: Arlene Caldas, Cecília Favali, Dorlene Aquino, Vera Vinhas, Johan van Weyenbergh, Cláudia Brodskyn, Jackson Costa, Manoel Barral-Netto, Aldina Barral

Published in: BMC Infectious Diseases | Issue 1/2005

Login to get access

Abstract

Background

Leishmaniasis remains a serious public health problem in several parts of the developing world. Effective prophylactic measurements are hampered by imprecise comprehension of different aspects of the disease, including its immunoregulation. A better comprehension of immunoregulation in human VL may be useful both for designing and evaluating immunoprophylaxis.

Methods

To explore immunoregulatory mechanisms, 20 visceral leishmaniasis (VL) patients were evaluated during active disease and at different periods up to one year after treatment determining their plasma cytokine levels, clinical parameters (palpable spleen and liver) and antibody levels.

Results

Elevated plasma levels of IFN-γ and of IL-12 p40 were observed during active disease, significantly decreasing after treatment whereas in vitro Leishmania antigen-stimulated IFN-γ production by PBMC exhibited an inverse pattern being low during disease and increasing steadily thereafter. Absence of IFN-γ activity is a hallmark of VL. The main candidate for blunting IFN-γ activity is IL-10, a cytokine highly elevated in plasma with sharp decrease after treatment. Activity of IL-10 is inferred by high levels of anti-Leishmania specific IgG1 and IgG3. TGF-β had elevated total, but not of active, levels lessening the likelihood of being the IFN-γ counterpart. Spleen or liver size presented a steady decrease but return to normal values at only 120 days after treatment. Anti-Leishmania IgG (total and subclasses) levels and DTH or Leishmania-stimulated lymphocyte proliferation conversion to positive also present a slow decrease after treatment. IL-6 plasma levels were elevated in only a few patients.

Conclusion

Taken together our results suggest that IFN-γ and IL-10 are the molecules most likely involved in determining fate of disease. After treatment, there is a long delay before the immune profile returns to normal what precludes using plasma cytokine levels as criteria of cure as simpler clinical evaluations, as a palpable spleen or liver, can be used.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM: Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res. 1998, 31: 143-148. 10.1590/S0100-879X1998000100020.CrossRefPubMed Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM: Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res. 1998, 31: 143-148. 10.1590/S0100-879X1998000100020.CrossRefPubMed
2.
go back to reference Carvalho EM, Badaro R, Reed SG, Jones TC, Johnson WDJ: Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest. 1985, 76: 2066-2069.CrossRefPubMedPubMedCentral Carvalho EM, Badaro R, Reed SG, Jones TC, Johnson WDJ: Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest. 1985, 76: 2066-2069.CrossRefPubMedPubMedCentral
3.
go back to reference Carvalho EM, Teixeira RS, Johnson WDJ: Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun. 1981, 33: 498-500.PubMedPubMedCentral Carvalho EM, Teixeira RS, Johnson WDJ: Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun. 1981, 33: 498-500.PubMedPubMedCentral
4.
go back to reference Carvalho EM, Bacellar O, Barral A, Badaro R, Johnson WDJ: Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Invest. 1989, 83: 860-864.CrossRefPubMedPubMedCentral Carvalho EM, Bacellar O, Barral A, Badaro R, Johnson WDJ: Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Invest. 1989, 83: 860-864.CrossRefPubMedPubMedCentral
5.
go back to reference Carvalho EM, Barral A, Pedral-Sampaio D, Barral-Netto M, Badaro R, Rocha H, Johnson WDJ: Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis. 1992, 165: 535-540.CrossRefPubMed Carvalho EM, Barral A, Pedral-Sampaio D, Barral-Netto M, Badaro R, Rocha H, Johnson WDJ: Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis. 1992, 165: 535-540.CrossRefPubMed
6.
go back to reference Sacks DL, Lal SL, Shrivastava SN, Blackwell J, Neva FA: An analysis of T cell responsiveness in Indian kala-azar. J Immunol. 1987, 138: 908-913.PubMed Sacks DL, Lal SL, Shrivastava SN, Blackwell J, Neva FA: An analysis of T cell responsiveness in Indian kala-azar. J Immunol. 1987, 138: 908-913.PubMed
7.
go back to reference Bacellar O, D'Oliveira AJ, Jeronimo S, Carvalho EM: IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine. 2000, 12: 1228-1231. 10.1006/cyto.2000.0694.CrossRefPubMed Bacellar O, D'Oliveira AJ, Jeronimo S, Carvalho EM: IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine. 2000, 12: 1228-1231. 10.1006/cyto.2000.0694.CrossRefPubMed
8.
go back to reference Hailu A, Menon JN, Berhe N, Gedamu L, Hassard TH, Kager PA, Olobo J, Bretscher PA: Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure. J Infect Dis. 2001, 184: 112-115. 10.1086/320994.CrossRefPubMed Hailu A, Menon JN, Berhe N, Gedamu L, Hassard TH, Kager PA, Olobo J, Bretscher PA: Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure. J Infect Dis. 2001, 184: 112-115. 10.1086/320994.CrossRefPubMed
9.
go back to reference Sundar S, Rosenkaimer F, Lesser ML, Murray HW: Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. J Infect Dis. 1995, 171: 992-996.CrossRefPubMed Sundar S, Rosenkaimer F, Lesser ML, Murray HW: Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. J Infect Dis. 1995, 171: 992-996.CrossRefPubMed
10.
go back to reference Hailu A, van der Poll T, Berhe N, Kager PA: Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg. 2004, 71: 561-567.PubMed Hailu A, van der Poll T, Berhe N, Kager PA: Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg. 2004, 71: 561-567.PubMed
11.
go back to reference Cenini P, Berhe N, Hailu A, McGinnes K, Frommel D: Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J Infect Dis. 1993, 168: 986-993.CrossRefPubMed Cenini P, Berhe N, Hailu A, McGinnes K, Frommel D: Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J Infect Dis. 1993, 168: 986-993.CrossRefPubMed
12.
go back to reference de Medeiros IM, Castelo A, Salomao R: Presence of circulating levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha in patients with visceral leishmaniasis. Rev Inst Med Trop Sao Paulo. 1998, 40: 31-34.PubMed de Medeiros IM, Castelo A, Salomao R: Presence of circulating levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha in patients with visceral leishmaniasis. Rev Inst Med Trop Sao Paulo. 1998, 40: 31-34.PubMed
13.
go back to reference Cillari E, Vitale G, Arcoleo F, D'Agostino P, Mocciaro C, Gambino G, Malta R, Stassi G, Giordano C, Milano S, et al: In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine. 1995, 7: 740-745. 10.1006/cyto.1995.0088.CrossRefPubMed Cillari E, Vitale G, Arcoleo F, D'Agostino P, Mocciaro C, Gambino G, Malta R, Stassi G, Giordano C, Milano S, et al: In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine. 1995, 7: 740-745. 10.1006/cyto.1995.0088.CrossRefPubMed
14.
go back to reference Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG: Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol. 1994, 152: 5949-5956.PubMed Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG: Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol. 1994, 152: 5949-5956.PubMed
15.
go back to reference Gantt KR, Schultz-Cherry S, Rodriguez N, Jeronimo SM, Nascimento ET, Goldman TL, Recker TJ, Miller MA, Wilson ME: Activation of TGF-beta by Leishmania chagasi: importance for parasite survival in macrophages. J Immunol. 2003, 170: 2613-2620.CrossRefPubMed Gantt KR, Schultz-Cherry S, Rodriguez N, Jeronimo SM, Nascimento ET, Goldman TL, Recker TJ, Miller MA, Wilson ME: Activation of TGF-beta by Leishmania chagasi: importance for parasite survival in macrophages. J Immunol. 2003, 170: 2613-2620.CrossRefPubMed
16.
go back to reference van der Poll T, Zijlstra EE, Mevissen M: Interleukin 6 during active visceral leishmaniasis and after treatment. Clin Immunol Immunopathol. 1995, 77: 111-114. 10.1016/0090-1229(95)90144-2.CrossRefPubMed van der Poll T, Zijlstra EE, Mevissen M: Interleukin 6 during active visceral leishmaniasis and after treatment. Clin Immunol Immunopathol. 1995, 77: 111-114. 10.1016/0090-1229(95)90144-2.CrossRefPubMed
17.
go back to reference Sundar S, Reed SG, Sharma S, Mehrotra A, Murray HW: Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg. 1997, 56: 522-525.PubMed Sundar S, Reed SG, Sharma S, Mehrotra A, Murray HW: Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg. 1997, 56: 522-525.PubMed
18.
go back to reference Barral-Netto M, Badaro R, Barral A, Almeida RP, Santos SB, Badaro F, Pedral-Sampaio D, Carvalho EM, Falcoff E, Falcoff R: Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J Infect Dis. 1991, 163: 853-857.CrossRefPubMed Barral-Netto M, Badaro R, Barral A, Almeida RP, Santos SB, Badaro F, Pedral-Sampaio D, Carvalho EM, Falcoff E, Falcoff R: Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J Infect Dis. 1991, 163: 853-857.CrossRefPubMed
19.
go back to reference Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM: Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med. 1989, 169: 59-72. 10.1084/jem.169.1.59.CrossRefPubMed Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM: Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med. 1989, 169: 59-72. 10.1084/jem.169.1.59.CrossRefPubMed
20.
go back to reference Heinzel FP, Sadick MD, Mutha SS, Locksley RM: Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci U S A. 1991, 88: 7011-7015.CrossRefPubMedPubMedCentral Heinzel FP, Sadick MD, Mutha SS, Locksley RM: Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci U S A. 1991, 88: 7011-7015.CrossRefPubMedPubMedCentral
21.
go back to reference Scott P: IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol. 1991, 147: 3149-3155.PubMed Scott P: IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol. 1991, 147: 3149-3155.PubMed
22.
go back to reference Barral-Netto M, Diez R, Badaro R, Sampaio D, Barral A, Carvalho EM, Falcoff E: Serum interferon activity of patients with leishmaniasis. Braz J Med Biol Res. 1989, 22: 1485-1487.PubMed Barral-Netto M, Diez R, Badaro R, Sampaio D, Barral A, Carvalho EM, Falcoff E: Serum interferon activity of patients with leishmaniasis. Braz J Med Biol Res. 1989, 22: 1485-1487.PubMed
23.
go back to reference Barral-Netto M, Barral A, Brownell CE, Skeiky YA, Ellingsworth LR, Twardzik DR, Reed SG: Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science. 1992, 257: 545-548.CrossRefPubMed Barral-Netto M, Barral A, Brownell CE, Skeiky YA, Ellingsworth LR, Twardzik DR, Reed SG: Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science. 1992, 257: 545-548.CrossRefPubMed
24.
go back to reference Barral A, Barral-Netto M, Yong EC, Brownell CE, Twardzik DR, Reed SG: Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci U S A. 1993, 90: 3442-3446.CrossRefPubMedPubMedCentral Barral A, Barral-Netto M, Yong EC, Brownell CE, Twardzik DR, Reed SG: Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci U S A. 1993, 90: 3442-3446.CrossRefPubMedPubMedCentral
25.
go back to reference Barral A, Teixeira M, Reis P, Vinhas V, Costa J, Lessa H, Bittencourt AL, Reed S, Carvalho EM, Barral-Netto M: Transforming growth factor-beta in human cutaneous leishmaniasis. Am J Pathol. 1995, 147: 947-954.PubMedPubMedCentral Barral A, Teixeira M, Reis P, Vinhas V, Costa J, Lessa H, Bittencourt AL, Reed S, Carvalho EM, Barral-Netto M: Transforming growth factor-beta in human cutaneous leishmaniasis. Am J Pathol. 1995, 147: 947-954.PubMedPubMedCentral
26.
go back to reference Bretscher PA, Wei G, Menon JN, Bielefeldt-Ohmann H: Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science. 1992, 257: 539-542.CrossRefPubMed Bretscher PA, Wei G, Menon JN, Bielefeldt-Ohmann H: Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science. 1992, 257: 539-542.CrossRefPubMed
27.
go back to reference Barral-Netto M, Barral A, Santos SB, Carvalho EM, Badaro R, Rocha H, Reed SG, Johnson WDJ: Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis. J Immunol. 1991, 147: 281-284.PubMed Barral-Netto M, Barral A, Santos SB, Carvalho EM, Badaro R, Rocha H, Reed SG, Johnson WDJ: Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis. J Immunol. 1991, 147: 281-284.PubMed
28.
go back to reference el Amin EM, Wright EP, Vlug A: Characterization of the humoral immune response in Sudanese leishmaniasis: specific antibody detected by class- and subclass-specific reagents. Clin Exp Immunol. 1986, 64: 14-19.PubMedPubMedCentral el Amin EM, Wright EP, Vlug A: Characterization of the humoral immune response in Sudanese leishmaniasis: specific antibody detected by class- and subclass-specific reagents. Clin Exp Immunol. 1986, 64: 14-19.PubMedPubMedCentral
29.
go back to reference Elassad AM, Younis SA, Siddig M, Grayson J, Petersen E, Ghalib HW: The significance of blood levels of IgM, IgA, IgG and IgG subclasses in Sudanese visceral leishmaniasis patients. Clin Exp Immunol. 1994, 95: 294-299.CrossRefPubMedPubMedCentral Elassad AM, Younis SA, Siddig M, Grayson J, Petersen E, Ghalib HW: The significance of blood levels of IgM, IgA, IgG and IgG subclasses in Sudanese visceral leishmaniasis patients. Clin Exp Immunol. 1994, 95: 294-299.CrossRefPubMedPubMedCentral
30.
go back to reference Ravindran R, Anam K, Bairagi BC, Saha B, Pramanik N, Guha SK, Goswami RP, Banerjee D, Ali N: Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy. Infect Immun. 2004, 72: 863-870. 10.1128/IAI.72.2.863-870.2004.CrossRefPubMedPubMedCentral Ravindran R, Anam K, Bairagi BC, Saha B, Pramanik N, Guha SK, Goswami RP, Banerjee D, Ali N: Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy. Infect Immun. 2004, 72: 863-870. 10.1128/IAI.72.2.863-870.2004.CrossRefPubMedPubMedCentral
31.
go back to reference Buchetont B, El-Safi SH, Hammad A, Kheir MM, Eudes N, Mirgani A, Dessein AJ, Mary C: Antileishmanial antibodies in an outbreak of visceral leishmaniasis in eastern Sudan: high antibody responses occur in resistant subjects and are not predictive of disease. Trans R Soc Trop Med Hyg. 2003, 97: 463-468. 10.1016/S0035-9203(03)90092-7.CrossRefPubMed Buchetont B, El-Safi SH, Hammad A, Kheir MM, Eudes N, Mirgani A, Dessein AJ, Mary C: Antileishmanial antibodies in an outbreak of visceral leishmaniasis in eastern Sudan: high antibody responses occur in resistant subjects and are not predictive of disease. Trans R Soc Trop Med Hyg. 2003, 97: 463-468. 10.1016/S0035-9203(03)90092-7.CrossRefPubMed
32.
go back to reference Chatterjee M, Basu K, Basu D, Bannerjee D, Pramanik N, Guha SK, Goswami RP, Saha SK, Mandal C: Distribution of IgG subclasses in antimonial unresponsive Indian kala-azar patients. Clin Exp Immunol. 1998, 114: 408-413. 10.1046/j.1365-2249.1998.00752.x.CrossRefPubMedPubMedCentral Chatterjee M, Basu K, Basu D, Bannerjee D, Pramanik N, Guha SK, Goswami RP, Saha SK, Mandal C: Distribution of IgG subclasses in antimonial unresponsive Indian kala-azar patients. Clin Exp Immunol. 1998, 114: 408-413. 10.1046/j.1365-2249.1998.00752.x.CrossRefPubMedPubMedCentral
33.
go back to reference Anam K, Afrin F, Banerjee D, Pramanik N, Guha SK, Goswami RP, Gupta PN, Saha SK, Ali N: Immunoglobulin subclass distribution and diagnostic value of Leishmania donovani antigen-specific immunoglobulin G3 in Indian kala-azar patients. Clin Diagn Lab Immunol. 1999, 6: 231-235.PubMedPubMedCentral Anam K, Afrin F, Banerjee D, Pramanik N, Guha SK, Goswami RP, Gupta PN, Saha SK, Ali N: Immunoglobulin subclass distribution and diagnostic value of Leishmania donovani antigen-specific immunoglobulin G3 in Indian kala-azar patients. Clin Diagn Lab Immunol. 1999, 6: 231-235.PubMedPubMedCentral
34.
go back to reference Gama ME, Costa JM, Pereira JC, Gomes CM, Corbett CE: Serum cytokine profile in the subclinical form of visceral leishmaniasis. Braz J Med Biol Res. 2004, 37: 129-136. 10.1590/S0100-879X2004000100018.CrossRefPubMed Gama ME, Costa JM, Pereira JC, Gomes CM, Corbett CE: Serum cytokine profile in the subclinical form of visceral leishmaniasis. Braz J Med Biol Res. 2004, 37: 129-136. 10.1590/S0100-879X2004000100018.CrossRefPubMed
35.
go back to reference Garraud O, Perraut R, Riveau G, Nutman TB: Class and subclass selection in parasite-specific antibody responses. Trends Parasitol. 2003, 19: 300-304. 10.1016/S1471-4922(03)00139-9.CrossRefPubMed Garraud O, Perraut R, Riveau G, Nutman TB: Class and subclass selection in parasite-specific antibody responses. Trends Parasitol. 2003, 19: 300-304. 10.1016/S1471-4922(03)00139-9.CrossRefPubMed
36.
go back to reference de Vries JE, Carballido JM, Sornasse T, Yssel H: Antagonizing the differentiation and functions of human T helper type 2 cells. Curr Opin Immunol. 1995, 7: 771-778. 10.1016/0952-7915(95)80046-8.CrossRefPubMed de Vries JE, Carballido JM, Sornasse T, Yssel H: Antagonizing the differentiation and functions of human T helper type 2 cells. Curr Opin Immunol. 1995, 7: 771-778. 10.1016/0952-7915(95)80046-8.CrossRefPubMed
37.
go back to reference Pisa P, Gennene M, Soder O, Ottenhoff T, Hansson M, Kiessling R: Serum tumor necrosis factor levels and disease dissemination in leprosy and leishmaniasis. J Infect Dis. 1990, 161: 988-991.CrossRefPubMed Pisa P, Gennene M, Soder O, Ottenhoff T, Hansson M, Kiessling R: Serum tumor necrosis factor levels and disease dissemination in leprosy and leishmaniasis. J Infect Dis. 1990, 161: 988-991.CrossRefPubMed
Metadata
Title
Balance of IL-10 and Interferon-γ plasma levels in human visceral leishmaniasis: Implications in the pathogenesis
Authors
Arlene Caldas
Cecília Favali
Dorlene Aquino
Vera Vinhas
Johan van Weyenbergh
Cláudia Brodskyn
Jackson Costa
Manoel Barral-Netto
Aldina Barral
Publication date
01-12-2005
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2005
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-5-113

Other articles of this Issue 1/2005

BMC Infectious Diseases 1/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.